U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
Pablo Pantaleoni, the Chief Digital Officer of LifeStance Health Group, Inc. (NASDAQ:LFST), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Pantaleoni sold a total of 35,505 shares of common stock across two transactions. The sales took place on March 7 and March 10, 2025, with share prices ranging from $7.29 to $7.64. The total value of these transactions amounted to $264,293. The timing is notable as InvestingPro data shows the stock has declined nearly 15% over the past week, with technical indicators suggesting oversold conditions.
Following these sales, Pantaleoni now holds 522,580 shares indirectly through a trust. The shares are part of the Pablo Pantaleoni Garcia and Clara Zuazu Vela Joint Revocable Trust, where Pantaleoni serves as a trustee. He retains direct ownership of 937,573 shares.
These transactions are part of routine financial management and investment strategies by company executives, often drawing interest from investors and analysts monitoring insider trading activities.
In other recent news, LifeStance Health reported its fourth-quarter 2024 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -$0.01, compared to the forecasted -$0.0383. The company’s revenue for the quarter was $325.5 million, surpassing the anticipated $313.91 million. LifeStance achieved its first-ever double-digit EBITDA margin during this period, marking a significant operational milestone. The company also announced plans to open 25-30 new centers in 2025 and anticipates achieving positive net income by 2026.
In terms of annual performance, LifeStance’s full-year 2024 revenue reached $1.251 billion, reflecting a 19% growth year-over-year, while adjusted EBITDA increased by 103% to $120 million. Analysts have noted the company’s strong financial performance, with Goldman Sachs and Morgan Stanley (NYSE:MS) analysts participating in the earnings call to discuss future strategies. The company also announced leadership changes, with Dave Borden taking over as CEO and Ryan McGrarty appointed as the new CFO.
Looking ahead, LifeStance projects its 2025 revenue to be between $1.400 billion and $1.440 billion, with adjusted EBITDA expected to range from $130 million to $150 million. The company remains focused on expanding its operations and enhancing clinician satisfaction, as evidenced by its strategic plans and leadership transitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.